In patients with diabetes, iGlarLixi improved SMPG, SD of SMPG, HBGI, AUCn, MAG, and MAGE versus insulin glargine at week 30.
In plain wordsIn patients with diabetes, iGlarLixi improved SMPG, SD of SMPG, HBGI, AUCn, MAG, and MAGE versus insulin glargine at week 30.
- Peptide
- Lixisenatide
- Outcome
- Direction not reportedGlycemic variability markers
- Study
n: not reported in source
- Comparator
- Insulin glargine
- Outcome group
- Glycemic control · Metabolic and weight
- Studied dose
- Dose not stated
Source sentences
Significant improvements were observed in SMPG, SD of SMPG, HBGI, AUCn, MAG and MAGE compared with iGlar, and in SMPG, HBGI and AUCn, compared with Lixi.
2 context sentences(design, population, supporting numbers)
The GV features that were measured were mean and SD of self-measured plasma glucose (SMPG), high blood glucose index (HBGI) and low blood glucose index, area under the SMPG curve for each patient (AUCn), mean absolute glucose (MAG) and mean amplitude of glycaemic excursions (MAGE).
By week 30, iGlarLixi improved all GV markers from baseline, with no increased hypoglycaemia risk.